Literature DB >> 17915849

Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.

Eric Stern1, Giulio G Muccioli, Barbara Bosier, Laurie Hamtiaux, Régis Millet, Jacques H Poupaert, Jean-Pierre Hénichart, Patrick Depreux, Jean-François Goossens, Didier M Lambert.   

Abstract

CB2 receptor selective ligands are becoming increasingly attractive drugs due to the potential role of this receptor in several physiopathological processes. Thus, the development of our previously described series of 4-oxo-1,4-dihydroquinoline-3-carboxamides was pursued with the aim to further characterize the structure-affinity and structure-functionality relationships of these derivatives. The influence of the side chain was investigated by synthesizing compounds bearing various carboxamido and keto substituents. On the other hand, the role of the quinoline central scaffold was studied by synthesizing several 6-, 7-, or 8-chloro-4-oxo-1,4-dihydroquinolines, as well as 4-oxo-1,4-dihydronaphthyridine and 4-oxo-1,4-dihydrocinnoline derivatives. The effect of these modifications on the affinity and functionality at the CB2 receptor was studied and allowed for the characterization of new selective CB2 receptor ligands.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17915849     DOI: 10.1021/jm070387h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis.

Authors:  Jamal El Bakali; Giulio G Muccioli; Mathilde Body-Malapel; Madjid Djouina; Frédérique Klupsch; Alina Ghinet; Amélie Barczyk; Nicolas Renault; Philippe Chavatte; Pierre Desreumaux; Didier M Lambert; Régis Millet
Journal:  ACS Med Chem Lett       Date:  2014-12-04       Impact factor: 4.345

2.  Catalyst-free multicomponent synthesis of novel adamantyl-containing tetrahydropyrimidine carboxylates.

Authors:  Utpalparna Kalita; Shunan Kaping; Jai Narain Vishwakarma
Journal:  Mol Divers       Date:  2016-01-21       Impact factor: 2.943

3.  CoMFA and CoMSIA analyses on 4-oxo-1,4-dihydroquinoline and 4-oxo-1,4-dihydro-1,5-, -1,6- and -1,8-naphthyridine derivatives as selective CB2 receptor agonists.

Authors:  Elena Cichero; Sara Cesarini; Luisa Mosti; Paola Fossa
Journal:  J Mol Model       Date:  2009-10-01       Impact factor: 1.810

4.  Quinolinonyl Non-Diketo Acid Derivatives as Inhibitors of HIV-1 Ribonuclease H and Polymerase Functions of Reverse Transcriptase.

Authors:  Antonella Messore; Angela Corona; Valentina Noemi Madia; Francesco Saccoliti; Valeria Tudino; Alessandro De Leo; Davide Ialongo; Luigi Scipione; Daniela De Vita; Giorgio Amendola; Ettore Novellino; Sandro Cosconati; Mathieu Métifiot; Marie-Line Andreola; Francesca Esposito; Nicole Grandi; Enzo Tramontano; Roberta Costi; Roberto Di Santo
Journal:  J Med Chem       Date:  2021-06-09       Impact factor: 7.446

5.  Design, synthesis, and biological evaluation of novel arylcarboxamide derivatives as anti-tubercular agents.

Authors:  Shahinda S R Alsayed; Shichun Lun; Giuseppe Luna; Chau Chun Beh; Alan D Payne; Neil Foster; William R Bishai; Hendra Gunosewoyo
Journal:  RSC Adv       Date:  2020-02-19       Impact factor: 4.036

Review 6.  Recent syntheses of 1,2,3,4-tetrahydroquinolines, 2,3-dihydro-4(1H)-quinolinones and 4(1H)-quinolinones using domino reactions.

Authors:  Baskar Nammalwar; Richard A Bunce
Journal:  Molecules       Date:  2013-12-24       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.